Accessibility Menu
Immix Biopharma logo

Immix Biopharma

(NASDAQ) IMMX

Current Price$9.70
Market Cap$512.61M
Since IPO (2021)+158%
5 YearN/A
1 Year+396%
1 Month+19%

Immix Biopharma Financials at a Glance

Market Cap

$512.61M

Revenue (TTM)

$0.00

Net Income (TTM)

$23.56M

EPS (TTM)

$-0.79

P/E Ratio

-12.31

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$9.70

Volume

41,272

Open

$9.35

Previous Close

$9.70

Daily Range

$9.12 - $10.06

52-Week Range

$1.34 - $11.61

IMMX News

No articles available.

IMMX: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Immix Biopharma

Industry

Biotechnology

Employees

21

CEO

Ilya Rachman, MD, PhD

Headquarters

Los Angeles, CA 90064, US

IMMX Financials

Key Financial Metrics (TTM)

Gross Margin

0%

Operating Margin

0%

Net Income Margin

0%

Return on Equity

-183%

Return on Capital

-3%

Return on Assets

-1%

Earnings Yield

-8.12%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$512.61M

Shares Outstanding

52.96M

Volume

41.27K

Short Interest

0.00%

Avg. Volume

873.32K

Financials (TTM)

Gross Profit

$0.00

Operating Income

$22.67M

EBITDA

$22.56M

Operating Cash Flow

$14.60M

Capital Expenditure

$1.18M

Free Cash Flow

$15.77M

Cash & ST Invst.

$17.68M

Total Debt

$1.07M

Immix Biopharma Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q3 2025YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$512.61M

N/A

Market Cap/Employee

$28.48M

N/A

Employees

18

N/A

Net Income

$7.59M

-6.1%

EBITDA

$7.48M

-1.5%

Quarterly Fundamentals

Name
Q3 2025YOY CHG

Net Cash

$14.84M

-20.2%

Accounts Receivable

$0.00

-100.0%

Inventory

$0.00

N/A

Long Term Debt

$965.05K

-6.0%

Short Term Debt

$141.28K

+125.3%

Return on Assets

-1.17%

N/A

Return on Invested Capital

-2.61%

N/A

Free Cash Flow

$6.28M

-45.7%

Operating Cash Flow

$5.91M

-46.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
SRZNSurrozen, Inc.
$26.63+3.70%
ZNTLZentalis Pharmaceuticals, Inc.
$2.56+1.79%
MGNXMacroGenics, Inc.
$2.90-2.68%
WHWKWhitehawk Therapeutics Inc
$3.59-5.77%

Trending Stocks

Symbol / CompanyPricePrice Chg
ITUBItaú Unibanco
$8.12+0.01%
MUMicron Technology
$444.59-0.04%
RIVNRivian Automotive
$16.11+0.04%
TAT&T
$27.76+0.01%

Questions About IMMX

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.